TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6897618
Drug: Bromhexin tablets
Normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexin tablets 8 mg
Study: 6897618
Drug: Bisolvon tablets
Normalized name: Bisolvon metabolite vIII
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisolvon tablets 8 mg
Study: 6897618
Drug: Bromhexine (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine (overall pharmacokinetics)
Study: 29160099
Drug: rAAV1-CMV-hGAA gene
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV1-CMV-hGAA gene therapy
Study: 17561982
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) in Turner syndrome
Study: 17561982
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives in controls
Study: 9822044
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment protocol (LTP) with PGE1: 2-hour infusions (60 microg PGE1, 5 days each week for 4 weeks), followed by twice a week for 4 weeks, then monitoring for 3 months.
Study: 9822044
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment protocol (STP) with PGE1: 2-hour infusion over 2 days (1st day: morning 20 microg, afternoon 40 microg; 2nd day: morning and afternoon 60 microg), followed by full dosage for subsequent cycles.
Study: 2644595
Drug: Clotrimazole 500
Normalized name: clotrimazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 500 mg vaginal suppositories, administered once weekly for 2 weeks
Study: 2644595
Drug: Clotrimazole 500
Normalized name: clotrimazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 500 mg vaginal tablets, administered once a month during prophylactic phase
Study: 2644595
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered once a month during prophylactic phase
Study: 30016185
Drug: LVHL2 (low-velocity,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVHL2 (low-velocity, high-load, twice-weekly)
Study: 30016185
Drug: LVHL1 (low-velocity,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVHL1 (low-velocity, high-load, once-weekly)
Study: 30016185
Drug: HVLL2 (high-velocity,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVLL2 (high-velocity, low-load, twice-weekly)
Study: 28151904
Drug: Ultrasound-guided interfascial
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided interfascial block (IFB) with 10 mL of 0.6% lidocaine
Study: 25995169
Drug: Icotinib administered
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib administered with food
Study: 25995169
Drug: Icotinib administered
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib administered without food
Study: 25995169
Drug: Icotinib pharmacokinetics
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib pharmacokinetics model
Study: 23956164
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (3 mg/kg/day of elemental iron and multivitamins)
Study: 19528561
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (elemental calcium, 1500 mg/d)
Study: 15383014
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of elemental iron per day
Study: 15383014
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of elemental iron per day
Study: 15383014
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of elemental iron (placebo)
Study: 11465525
Drug: Granisetron (1-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1-1.5 mg)
Study: 9682398
Drug: cell culture-derived
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: cell culture-derived vaccine
Study: 9682398
Drug: egg-derived vaccine
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: egg-derived vaccine
Study: 3410479
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (20 g)
Study: 17916665
Drug: Amlodipine 5-10
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5-10 mg with perindopril 4-8 mg added as needed
Study: 17916665
Drug: Atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50-100 mg with bendroflumethiazide 1.25-2.5 mg and potassium added as needed
Study: 16433964
Drug: Milk containing
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk containing 2.0 g CPP-ACP/l
Study: 16433964
Drug: Milk containing
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk containing 5.0 g CPP-ACP/l
Study: 14657887
Drug: Peanut skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut skin prick tests (SPTs) and oral peanut challenges for groups 2 and 4 with positive SPT responses; peanut-specific IgE measurement for groups 2 and 4 with IgE levels < 15 kU/L.
Study: 9099448
Drug: Flunarizine 30
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 30 mg oral dose
Study: 3096723
Drug: Methohexitone 1.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexitone 1.5-2 mg kg‐1
Study: 29316946
Drug: Combined cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive behavioural group psychotherapy and physiotherapy (9 weekly sessions with a 4-week break between modules)
Study: 12666731
Drug: 1% lindane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lindane shampoo and oral trimethoprim/sulfamethoxazole (group 2)
Study: 10547175
Drug: Antidepressants (sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (sertraline hydrochloride)
Study: 10547175
Drug: Combined exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined exercise and medication
Study: 8683243
Drug: Amifostine (910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (910 mg/m2)
Study: 1805048
Drug: Imipenem/cilastatine (IPM/CS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatine (IPM/CS) 1 g twice daily
Study: 1805048
Drug: Latamoxef (LMOX)
Normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Latamoxef (LMOX) 2 g plus Tobramycin (TOB) 90 mg twice daily
Study: 6402917
Drug: Oral tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral tegafur (1 gm/m2/days 1‐21)
Study: 6402917
Drug: 5-fluorouracil (5-Fu,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5-Fu, 500 mg/m2/days 1‐4, then 250 mg/m2 on days 6, 8, 10, 12)
Study: 6402917
Drug: Oral tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral tegafur
Study: 29105958
Drug: Nebivolol/valsartan SPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol/valsartan SPC (5 mg/80 mg)
Study: 29105958
Drug: Nebivolol/valsartan SPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol/valsartan SPC (5 mg/160 mg)
Study: 29105958
Drug: Nebivolol/valsartan SPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol/valsartan SPC (10 mg/160 mg)
Study: 29105958
Drug: Nebivolol/valsartan SPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol/valsartan SPC (10 mg/320 mg)
Study: 29105958
Drug: Comparator weighted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator weighted average (non-β-blocker/renin-angiotensin-aldosterone system inhibitor SPCs)
Study: 17272996
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose interferon-alpha (3 MU three times per week for 12 months)
Study: 17272996
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interferon-alpha (5 MU three times per week for 6 months)
Study: 16095546
Drug: Water-based exercise
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based exercise treatment
Study: 2188928
Drug: Mitoxantrone 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12 mg/m2 i.v. every three weeks
Study: 483111
Drug: 20% mannitol-bisacodyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol-bisacodyl solution for oral use
Study: 31321771
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 40 mg once daily
Study: 28624340
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 µg daily)
Study: 11728945
Drug: Selective COX‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective COX‐2 inhibitors
Study: 24620015
Drug: Nonselective COX‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective COX‐2 inhibitors
Study: 12066422
Drug: Interpretation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpretation of target symbols (e.g., interpreting '>' as a right-pointing arrow or as a headlight shining to the left)
Study: 9800669
Drug: hMG/hCG therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG/hCG therapy
Study: 2515625
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg), 10 weeks after treatment
Study: 2515625
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg), 6 weeks after treatment
Study: 2515625
Drug: Praziquantel (double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (double dose of 40 mg/kg), within 10 days after treatment
Study: 78718
Drug: Triprolidine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine (2.5 mg)
Study: 28606735
Drug: Prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg twice daily
Study: 28606735
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg daily
Study: 19729401
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group with treatment intensification
Study: 19729401
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with treatment intensification
Study: 19729401
Drug: Both study
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both study groups with proper treatment intensification
Study: 17250690
Drug: Anti-oxidant supplement
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-oxidant supplement (beta-carotene 9 mg/day, vitamin C 1500 mg/day, vitamin E 130 mg/day, zinc 45 mg/day, selenium 76 microg/day, garlic 150 mg/day)
Study: 9754182
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin A (CsA) 2% in maize oil
Study: 29317666
Drug: Rituximab 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 0.1 mg/m2
Study: 29317666
Drug: Rituximab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 0.3 mg/m2
Study: 29317666
Drug: Proposed biosimilar
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed biosimilar 0.3 mg/m2
Study: 29317666
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product 0.3 mg/m2
Study: 29317666
Drug: Rituximab 1
Normalized name: rituximab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 1 mg/m2
Study: 28424854
Drug: Narrative Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Enhancement and Cognitive Therapy (NECT) as an add-on to treatment as usual
Study: 19299763
Drug: Preoperative BNP
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative BNP elevation > or =50 pg/mL
Study: 19299763
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of preoperative BNP elevation > or =50 pg/mL and postoperative cTn I elevation > or =2 ng/mL
Study: 11166379
Drug: Therapies aimed
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies aimed at inhibiting lymphoid cell apoptosis
Study: 11166379
Drug: Anti-cytokine and
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-cytokine and anti-inflammatory therapies
Study: 8573926
Drug: Moist toilet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moist toilet paper preparation
Study: 8573926
Drug: Recycled toilet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recycled toilet paper preparation
Study: 8573926
Drug: Conventional toilet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional toilet paper preparation
Study: 2561015
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg per os)
Study: 25452062
Drug: Cessation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation group therapy
Study: 21692408
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg/kg + Dexamethasone 4 mg
Study: 21692408
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg/kg + Dexamethasone 8 mg
Study: 19491220
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (2 mg/d sc; n = 22)
Study: 17326082
Drug: Double-dose (D(D))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose (D(D)) Gd-DTPA
Study: 17326082
Drug: Single-dose (D(S))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (D(S)) Gd-DTPA
Study: 15075538
Drug: IL-2 immunotherapy
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 immunotherapy with HAART
Study: 7919965
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with IFN-alpha and IL-2
Study: 7919965
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (surgery or chemotherapy)
Study: 3290263
Drug: Amiloride 5
Normalized name: amiloride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 5 mg twice a day
Study: 30171747
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin monotherapy (HMET) 1,500 mg
Study: 30171747
Drug: Low-dose metformin/linagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose metformin/linagliptin combination therapy (LMET + DPP4) 750 mg metformin + 5 mg linagliptin
Study: 21712672
Drug: Low-dose low-molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose low-molecular weight heparin (LMWH)
Study: 19291301
Drug: Fixed-dose AS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose AS (25 mg)/AQ (67.5 mg)
Study: 19291301
Drug: Loose AS
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose AS (50 mg) + AQ (153 mg)
Study: 19291301
Drug: Fixed-dose AS/AQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose AS/AQ
Study: 17355631
Drug: Ganciclovir treatment
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir treatment for 21 days
Study: 9689189
Drug: Ipriflavone, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone, 200 mg three times daily
Study: 8279371
Drug: Alteplase (rt-PA)
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase (rt-PA) 100 mg/3 hours (adjusted for body weight < 65 kg)
Study: 8279371
Drug: Heparin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (dose adjusted to maintain therapeutic partial thromboplastin time)
Study: 2638321
Drug: Glycine-fortified ORS
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine-fortified ORS at a concentration of 111 mmol/L (8.4 g/L)
Study: 30742834
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg MB‐MMX
Study: 24673054
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg, once a day)
Study: 22764339
Drug: Two‐wave MLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two‐wave MLS laser irradiation (dose 6.6 J/point)
Study: 22764339
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (simulated laser therapy without actual irradiation)
Study: 11849576
Drug: Ropivacaine 1
Normalized name: ROPivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1 mg x ml(-1)
Study: 11849576
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg x ml(-1)
Study: 11849576
Drug: Ropivacaine 3
Normalized name: fentanyl-ropivacaine 3 mcg/mL-0.1%-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 3 mg x ml(-1)
Study: 28179255
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) + l-NAME
Study: 28179255
Drug: Losartan (LOS)
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan (LOS) + l-NAME
Study: 28179255
Drug: Manidipine (MANI)
Normalized name: manidipine
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine (MANI) + l-NAME
Study: 23919898
Drug: Olanzapine (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10-40 mg/day)
Study: 14735129
Drug: High-dose (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (2.5 x seizure threshold) bilateral (BL) ECT
Study: 14735129
Drug: High-dose (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (6 x seizure threshold) RUL ECT
Study: 14735129
Drug: RUL ECT
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RUL ECT (all doses)
Study: 11179154
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention with two individual treatment sessions and two telephone follow up calls, supported by a comprehensive educational pack.
Study: 11179154
Drug: Minimum intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minimum intervention group (no further treatment).
Study: 8118539
Drug: Albuterol treatment
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol treatment (two puffs from a metered-dose inhaler with spacer at 20-minute intervals)
Study: 8118539
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (two puffs from a metered-dose inhaler with spacer at 20-minute intervals)
Study: 24299257
Drug: Early physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physical therapy intervention (ePT) consisting primarily of manual therapy, exercise, and modalities.
Study: 24299257
Drug: Usual podiatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual podiatric care (uPOD) consisting primarily of a stretching handout, medication, injections, and orthotics.
Study: 24299257
Drug: Early physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physical therapy intervention (ePT)
Study: 12850362
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B streptococcal type III CPS-TT conjugate vaccine
Study: 10717782
Drug: One implant
Normalized name: Testosterone Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: One implant of MENT acetate
Study: 10717782
Drug: Two implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two implants of MENT acetate
Study: 10717782
Drug: Four implants
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four implants of MENT acetate
Study: 1718693
Drug: Gallopamil (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (50mg 3 times daily)
Study: 1718693
Drug: Nifedipine (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20mg 3 times daily)
Study: 1718693
Drug: Gallopamil (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (100mg twice daily)
Study: 1718693
Drug: Nifedipine (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20mg twice daily)
Study: 6152885
Drug: Intercostal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve blockades (ICB) with 18-28 ml of plain bupivacaine 0.5% (1.30-1.82 mg kg-1)
Study: 29979283
Drug: Agonist-Antagonist Paired
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agonist-Antagonist Paired Set (PS)
Study: 21270204
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of PFF with insulin sensitivity and β-cell function
Study: 14979610
Drug: MLBL (immunostimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLBL (immunostimulating therapy) - one sublingual tablet per day for 10 consecutive days per month for 3 months
Study: 14979610
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - one sublingual tablet of taste masked placebo per day for 10 consecutive days per month for 3 months
Study: 3089941
Drug: Phenoxymethylpenicillin 2
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin 2 g b.i.d. for ten days
Study: 3089941
Drug: Phenoxymethylpenicillin 2
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin 2 g b.i.d. and metronidazole 0.8 g b.i.d. for ten days